Gilead's Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data ...

Retrieved on: 2021-12-16 19:49:40

Tags for this article:

Clinical medicine

Medicine

Chimeric antigen receptor T cell

Kite Pharma

Brexucabtagene autoleucel

Tisagenlecleucel

United States

Click the tags to see associated articles and topics

Gilead's Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data .... View article details on hiswai:

Excerpt

For Gilead Sciences' Yescarta, that indication could mean $1.5 billion in sales over time. That's the projection analysts at RBC Capital Markets made ...

Article found on: www.fiercepharma.com

View Original Article